• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

随着时间的推移,试验招募和实施面临的挑战越来越大。

Increasing challenges to trial recruitment and conduct over time.

机构信息

Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.

Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

出版信息

Epilepsia. 2023 Oct;64(10):2625-2634. doi: 10.1111/epi.17716. Epub 2023 Jul 25.

DOI:10.1111/epi.17716
PMID:37440282
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10592378/
Abstract

OBJECTIVE

This study was undertaken to evaluate how the challenges in the recruitment and retention of participants in clinical trials for focal onset epilepsy have changed over time.

METHODS

In this systematic analysis of randomized clinical trials of adjunct antiseizure medications for medication-resistant focal onset epilepsy, we evaluated how the numbers of participants, sites, and countries have changed since the first such trial in 1990. We also evaluated the proportion of participants who completed each trial phase and their reasons for early trial exit. We analyzed these trends using mixed effects generalized linear models accounting for the influence of the number of trial sites and trial-specific variability.

RESULTS

The number of participants per site has steadily decreased over decades, with recent trials recruiting fewer than five participants per site (reduction by .16 participants/site/year, p < .0001). Fewer participants also progressed from recruitment to randomization over time (odds ratio = .94/year, p = .014). Concurrently, there has been an increase in the placebo response over time (increase in median percent reduction of .4%/year, p = .02; odds ratio of increase in 50% responder rate of 1.03/year, p = .02), which was not directly associated with the number of sites per trial (p > .20).

SIGNIFICANCE

This historical analysis highlights the increasing challenges with participant recruitment and retention, as well as increasing placebo response. It serves as a call to action to change clinical trial design to address these challenges.

摘要

目的

本研究旨在评估随着时间的推移,局灶性癫痫发作临床试验中参与者招募和保留所面临的挑战发生了怎样的变化。

方法

在这项针对药物难治性局灶性癫痫发作辅助抗癫痫药物的随机临床试验的系统分析中,我们评估了自 1990 年首例此类试验以来,参与者人数、试验地点和国家数量的变化情况。我们还评估了每个试验阶段完成的参与者比例及其提前退出试验的原因。我们使用混合效应广义线性模型分析了这些趋势,该模型考虑了试验地点数量和试验特异性变异性的影响。

结果

每个试验点的参与者人数在几十年中稳步下降,最近的试验每个试验点的参与者人数不到 5 人(每年减少.16 名参与者/试验点,p<0.0001)。随着时间的推移,从招募到随机分组的参与者也越来越少(比值比=0.94/年,p=0.014)。同时,随着时间的推移,安慰剂效应也在增加(中位数百分比降低增加.4%/年,p=0.02;50%应答率增加的优势比为 1.03/年,p=0.02),但这与每个试验的试验点数量没有直接关联(p>0.20)。

意义

这项历史分析强调了参与者招募和保留方面的挑战不断增加,以及安慰剂效应的增加。它呼吁改变临床试验设计,以应对这些挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd45/10592378/f9aecda07713/nihms-1918076-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd45/10592378/f0d5148a3ea5/nihms-1918076-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd45/10592378/1605b059aa66/nihms-1918076-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd45/10592378/f9aecda07713/nihms-1918076-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd45/10592378/f0d5148a3ea5/nihms-1918076-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd45/10592378/1605b059aa66/nihms-1918076-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd45/10592378/f9aecda07713/nihms-1918076-f0003.jpg

相似文献

1
Increasing challenges to trial recruitment and conduct over time.随着时间的推移,试验招募和实施面临的挑战越来越大。
Epilepsia. 2023 Oct;64(10):2625-2634. doi: 10.1111/epi.17716. Epub 2023 Jul 25.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
4
Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials.研究拉考沙胺的临床实用性:三项 II/III 期临床试验的汇总分析。
CNS Drugs. 2010 Dec;24(12):1041-54. doi: 10.2165/11586830-000000000-00000.
5
Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.拉莫三嗪辅助治疗儿童和青少年原发性全面性强直阵挛发作。
Pediatrics. 2006 Aug;118(2):e371-8. doi: 10.1542/peds.2006-0148. Epub 2006 Jul 17.
6
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
7
Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: A phase III randomized, double-blind, placebo-controlled trial.在未得到控制的局灶性发作性癫痫的成年亚洲患者中,附加使用溴维曲坦的疗效、安全性和耐受性:一项 III 期随机、双盲、安慰剂对照试验。
Epilepsia Open. 2024 Jun;9(3):1007-1020. doi: 10.1002/epi4.12929. Epub 2024 Apr 4.
8
Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.布瓦西坦作为成人部分性癫痫未控制患者的附加治疗:一项 III 期随机、双盲、安慰剂对照试验。
Epilepsia. 2014 Jan;55(1):57-66. doi: 10.1111/epi.12433. Epub 2013 Nov 8.
9
A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial.一项评估 ICU 收治的 COVID-19 患者静脉用褪黑素的疗效和安全性的 II 期、单中心、双盲、随机安慰剂对照试验(MelCOVID 研究):一项随机对照试验研究方案的结构摘要。
Trials. 2020 Aug 5;21(1):699. doi: 10.1186/s13063-020-04632-4.
10
ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.羟氯喹用于 COVID-19 传染病的化学预防(PROLIFIC)以预防一线医护人员感染 COVID-19:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jul 2;21(1):604. doi: 10.1186/s13063-020-04543-4.

引用本文的文献

1
Blueprint for clinical N-of-1 strategies with off-label precision treatments in monogenic epilepsies.单基因癫痫中应用超说明书精准治疗的临床单病例N-of-1策略蓝图。
Orphanet J Rare Dis. 2025 Jun 16;20(1):309. doi: 10.1186/s13023-025-03750-z.
2
Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of focal seizures.随机分组前癫痫发作计数设计时间充分评估了吡仑帕奈治疗局灶性癫痫发作的安全性和耐受性。
Epilepsia. 2025 May 15. doi: 10.1111/epi.18460.
3
Factors associated with placebo response rate in randomized controlled trials of antiseizure medications for focal epilepsy.

本文引用的文献

1
Appropriate selection of participants for clinical trials in epilepsy.癫痫临床试验中参与者的恰当选择。
Lancet Neurol. 2023 Jul;22(7):554-555. doi: 10.1016/S1474-4422(23)00202-8.
2
Time-to-event clinical trial designs: Existing evidence and remaining concerns.时间事件临床试验设计:现有证据和尚存问题。
Epilepsia. 2023 Jul;64(7):1699-1708. doi: 10.1111/epi.17621. Epub 2023 May 2.
3
Reasons for ineligibility for clinical trials of patients with medication-resistant epilepsy.药物难治性癫痫患者临床试验排除的原因。
局灶性癫痫抗癫痫药物随机对照试验中与安慰剂反应率相关的因素。
Epilepsia. 2025 Feb;66(2):407-416. doi: 10.1111/epi.18197. Epub 2024 Dec 21.
4
The present and future of seizure detection, prediction, and forecasting with machine learning, including the future impact on clinical trials.利用机器学习进行癫痫发作检测、预测和预报的现状与未来,包括其对临床试验的未来影响。
Front Neurol. 2024 Jul 11;15:1425490. doi: 10.3389/fneur.2024.1425490. eCollection 2024.
5
Demonstration of Group-Level and Individual-Level Efficacy Using Time-to-Event Designs for Clinical Trials of Antiseizure Medications.使用事件时间设计展示抗癫痫药物临床试验的群组水平和个体水平疗效。
Neurology. 2024 Aug 27;103(4):e209713. doi: 10.1212/WNL.0000000000209713. Epub 2024 Jul 25.
6
Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of primary generalized tonic-clonic seizures.随机分组前癫痫发作次数的评估充分考察了吡仑帕奈治疗原发性全面强直-阵挛发作的安全性和耐受性。
Epilepsia. 2024 Aug;65(8):2412-2422. doi: 10.1111/epi.18023. Epub 2024 Jun 12.
7
Challenges and directions in epilepsy diagnostics and therapeutics: Proceedings of the 17th Epilepsy Therapies and Diagnostics Development conference.癫痫诊断与治疗中的挑战与方向:第17届癫痫治疗与诊断发展会议论文集
Epilepsia. 2024 Apr;65(4):846-860. doi: 10.1111/epi.17875. Epub 2024 Jan 5.
Epilepsia. 2023 May;64(5):e56-e60. doi: 10.1111/epi.17568. Epub 2023 Mar 17.
4
Enrollment of Participants From Marginalized Racial and Ethnic Groups: A Comparative Assessment of the STEADY-PD III and SURE-PD3 Trials.来自边缘化种族和族裔群体的参与者招募:对STEADY-PD III和SURE-PD3试验的比较评估。
Neurol Clin Pract. 2023 Feb;13(1):e200113. doi: 10.1212/CPJ.0000000000200113. Epub 2023 Jan 18.
5
New evidence in adjunctive treatment of focal-onset seizures in adults: a critical appraisal.成人局灶性发作辅助治疗的新证据:一项批判性评估。
Glob Reg Health Technol Assess. 2022 Jun 28;9(Suppl 2):14-19. doi: 10.33393/grhta.2022.2420. eCollection 2022 Jan-Dec.
6
Flexible realistic simulation of seizure occurrence recapitulating statistical properties of seizure diaries.灵活真实地模拟发作再现发作日记统计特征的发作。
Epilepsia. 2023 Feb;64(2):396-405. doi: 10.1111/epi.17471. Epub 2022 Dec 4.
7
Effectiveness and safety of perampanel as adjunctive therapy among Chinese patients with focal-onset epilepsy: A real-world prospective observational study.普瑞巴林辅助治疗中国局灶性癫痫患者的有效性和安全性:一项真实世界前瞻性观察研究。
Epilepsy Behav. 2022 Nov;136:108937. doi: 10.1016/j.yebeh.2022.108937. Epub 2022 Oct 7.
8
Efficacy and safety of adjunctive padsevonil in adults with drug-resistant focal epilepsy: Results from two double-blind, randomized, placebo-controlled trials.帕德伐尼辅助治疗耐药性局灶性癫痫成人患者的疗效和安全性:两项双盲、随机、安慰剂对照试验的结果。
Epilepsia Open. 2022 Dec;7(4):758-770. doi: 10.1002/epi4.12656. Epub 2022 Oct 22.
9
What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?阿尔茨海默病临床试验中多元化招募的目标应该是什么?
JAMA Neurol. 2022 Nov 1;79(11):1097-1098. doi: 10.1001/jamaneurol.2022.2274.
10
EEG-Driven Prediction Model of Oxcarbazepine Treatment Outcomes in Patients With Newly-Diagnosed Focal Epilepsy.新诊断局灶性癫痫患者奥卡西平治疗结局的脑电图驱动预测模型
Front Med (Lausanne). 2022 Jan 3;8:781937. doi: 10.3389/fmed.2021.781937. eCollection 2021.